LifeStance Health Files 8-K on Operations & Financial Condition

TL;DR

**LifeStance just filed an 8-K, signaling upcoming financial results that could move the stock.**

AI Summary

LifeStance Health Group, Inc. filed an 8-K on February 2, 2024, reporting on 'Results of Operations and Financial Condition' and 'Other Events.' This filing indicates that the company is likely to release or discuss its financial performance soon, which is crucial for investors to understand the company's health and future prospects. For shareholders, this means upcoming financial disclosures could impact the stock price (LFST) depending on whether the results meet or miss expectations.

Why It Matters

This filing signals that LifeStance Health Group, Inc. is preparing to disclose important financial information, which will directly influence investor perception and the stock's valuation.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying event (upcoming financial results) carries inherent market risk depending on the disclosed performance.

Analyst Insight

A smart investor would monitor LifeStance Health Group, Inc.'s upcoming announcements for detailed financial results, as this 8-K signals their imminent release, and prepare to analyze the performance metrics for potential investment decisions.

Key Players & Entities

• LifeStance Health Group, Inc. (company) — the registrant filing the 8-K
• February 2, 2024 (date) — date of earliest event reported and filing date
• 001-40478 (other) — Commission File Number for LifeStance Health Group, Inc.
• LFST (other) — trading symbol for LifeStance Health Group, Inc. Common Stock
• The Nasdaq Stock Market LLC (other) — exchange where LifeStance Health Group, Inc. Common Stock is registered

Forward-Looking Statements

• LifeStance Health Group, Inc. will release its detailed financial results for a recent period soon. (LifeStance Health Group, Inc.) — high confidence, target: Q1 2024
• The LFST stock price will experience volatility following the release of the financial results. (LFST) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share LFST The Nasdaq Stock Mar
• $50 million — r of 2023. As previously disclosed, the $50 million settlement consisted of two payments of
• $25 million — settlement consisted of two payments of $25 million each, with the initial payment made in
• $20 million — payment made in October 2023, of which $20 million was covered by insurance, and the secon
• $79 million — urth quarter of 2023 with approximately $79 million in cash and cash equivalents and $290 m
• $290 million — illion in cash and cash equivalents and $290 million in long-term debt. During the fourth qu
• $33 million — fourth quarter of 2023, LifeStance drew $33 million of debt under its existing credit facil
• $58 million — debt capacity under those facilities of $58 million as of December 31, 2023. LifeStance i

Filing Documents

• d701308d8k.htm (8-K) — 24KB
• 0001193125-24-022199.txt ( ) — 143KB
• lfst-20240202.xsd (EX-101.SCH) — 3KB
• lfst-20240202_lab.xml (EX-101.LAB) — 18KB
• lfst-20240202_pre.xml (EX-101.PRE) — 11KB
• d701308d8k_htm.xml (XML) — 4KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. LifeStance Health Group, Inc. Date: February 2, 2024 By: /s/ Ryan Pardo Name: Ryan Pardo Title: Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR